Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Documenti analoghi

• The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
  di: Ma, Liying, et al.
  Pubblicazione: (2020)
• Dual PI3K and HDAC inhibitor, CUDC-907, effectively inhibits endometrial cancer growth in vitro and in vivo
  di: Xudong Zhang, et al.
  Pubblicazione: (2025-11-01)
• CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
  di: Hu, Cheng, et al.
  Pubblicazione: (2020)
• Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression
  di: Luca Hegedüs, et al.
  Pubblicazione: (2025-10-01)
• The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
  di: Li, Xinyu, et al.
  Pubblicazione: (2020)